Rock Springs Capital Management LP 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-22 4:00 pm Purchase |
2024-11-18 | 13G | Aclaris Therapeutics, Inc. ACRS |
Rock Springs Capital Management LP | 6,761,861 6.320% |
3,763,366 (+125.51%) |
Filing |
| 2024-02-14 2:06 pm Sale |
2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
Rock Springs Capital Management LP | 2,998,495 4.230% |
-962,754 (-24.30%) |
Filing |
| 2023-02-14 2:49 pm Purchase |
2022-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
Rock Springs Capital Management LP | 3,961,249 5.940% |
99,902 (+2.59%) |
Filing |
| 2022-02-14 6:22 pm Purchase |
2021-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
Rock Springs Capital Management LP | 3,861,347 6.310% |
1,185,247 (+44.29%) |
Filing |
| 2021-02-16 4:32 pm Purchase |
2020-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS |
Rock Springs Capital Management LP | 2,676,100 6.240% |
462,244 (+20.88%) |
Filing |
| 2020-10-26 4:49 pm Purchase |
2020-10-14 | 13G | Aclaris Therapeutics, Inc. ACRS |
Rock Springs Capital Management LP | 2,213,856 5.180% |
613,856 (+38.37%) |
Filing |